The FDA just ordered new warnings on Ozempic, Mounjaro, Wegovy, and other popular weight-loss and diabetes drugs. This time, the concern is something nobody wants to lose: THEIR EYESIGHT.
Millions of Americans have turned to these medications to manage diabetes, lose weight, and improve their health.
For many people, they’ve been life-changing.
But the FDA is now warning about a potential increased risk of a rare eye condition called NAION, which can cause sudden, painless vision loss in one eye. In some cases, that damage can be permanent.
And here’s what makes this especially concerning.
The condition can strike without pain or much warning. Someone might go to bed seeing normally and wake up with part of their vision missing.
The FDA reviewed data from 126 clinical trials and found a higher rate of this condition among people taking GLP-1 medications compared with those in the comparison groups.
Now, it’s important to put this in perspective.
The condition is rare, and researchers have not established that these drugs directly cause it.
These medications also provide significant health benefits, particularly for people managing serious conditions like diabetes.
But that doesn’t mean patients shouldn’t know about potential risks.
If you’re taking one of these medications, don’t stop treatment without discussing it with your doctor. And if you experience sudden changes in your vision, seek medical attention immediately.
People deserve to know the possible risks of the medications they’re putting into their bodies. Not just the benefits advertised on television.
Because making an informed decision about your health means knowing both sides of the story.
Do you think drug companies and doctors do enough to explain potential side effects before people start taking these medications? 👇